Medical Information
United Kingdom
 

This site is intended for UK healthcare professionals and the information provided is not intended as medical advice.

Responsibility for patient care resides with the healthcare professional.

This content is intended for UK healthcare professionals. Would you like to proceed?

Enter question keywords

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

This medicinal product has been authorised under a conditional approval scheme. This means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed at least every year and this Summary of Product Characteristics will be updated as necessary.

Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)) was previously called COVID-19 mRNA Vaccine BNT162b2 and supplied under a Regulation 174 temporary supply authorisation. Following conditional Marketing Authorisation, the vaccine is now known by the brand name Comirnaty. If you have a question regarding the COVID-19 mRNA Vaccine BNT162b2 please submit an enquiry on our webform and clearly state this in the question field. The product label information for COVID-19 mRNA Vaccine BNT162b2 can be accessed on Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 - GOV.UK (www.gov.uk)

Healthcare Professionals located in Northern Ireland

If you are a Healthcare Professional based in Northern Ireland with a question on Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)), please submit your enquiry on our webform and clearly state this in the question field. The Comirnaty Summary of Product Characteristics for Northern Ireland can be accessed on https://www.emcmedicines.com/en-gb/northernireland

The information provided below is for customers located in Great Britain.

This medicinal product has been authorised under a conditional approval scheme. This means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed at least every year and the Summary of Product Characteristics will be updated as necessary.

Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)) was previously called COVID-19 mRNA Vaccine BNT162b2 and supplied under a Regulation 174 temporary supply authorisation. Following conditional Marketing Authorisation, the vaccine is now known by the brand name Comirnaty. If you have a question regarding the COVID-19 mRNA Vaccine BNT162b2 please submit an enquiry on our webform and clearly state this in the question field. The product label information for COVID-19 mRNA Vaccine BNT162b2 can be accessed on Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 - GOV.UK (www.gov.uk)

Healthcare Professionals located in Northern Ireland

If you are a Healthcare Professional based in Northern Ireland with a question on Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)), please submit your enquiry on our webform and clearly state this in the question field. The Comirnaty Summary of Product Characteristics for Northern Ireland can be accessed on https://www.emcmedicines.com/en-gb/northernireland

The information provided below is for customers located in Great Britain.

COMIRNATY (Covid-19 mRNA vaccine)

Enter question keywords

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

This medicinal product has been authorised under a conditional approval scheme. This means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed at least every year and this Summary of Product Characteristics will be updated as necessary.

Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)) was previously called COVID-19 mRNA Vaccine BNT162b2 and supplied under a Regulation 174 temporary supply authorisation. Following conditional Marketing Authorisation, the vaccine is now known by the brand name Comirnaty. If you have a question regarding the COVID-19 mRNA Vaccine BNT162b2 please submit an enquiry on our webform and clearly state this in the question field. The product label information for COVID-19 mRNA Vaccine BNT162b2 can be accessed on Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 - GOV.UK (www.gov.uk)

Healthcare Professionals located in Northern Ireland

If you are a Healthcare Professional based in Northern Ireland with a question on Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)), please submit your enquiry on our webform and clearly state this in the question field. The Comirnaty Summary of Product Characteristics for Northern Ireland can be accessed on https://www.emcmedicines.com/en-gb/northernireland

The information provided below is for customers located in Great Britain.

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Reporting an adverse event for the Covid-19 mRNA vaccine